Acceleron Pharma Inc: Developing TGF-beta therapeutics to treat serious and rare diseases. Lead therapeutic candidate in hematology, luspatercept, under a global partnership with Celgene, reported positive Phase 3 MEDALIST and BELIEVE trial results, and continues to advance multiple Ph2 and Ph3 trials for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. The Company has additional candidates advancing across multiple Phase 2 clinical trials for neuromuscular and pulmonary diseases.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III
Disease Space
Hematology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology, Pharmaceuticals
Listing
Public, USA
Market Cap
500MM +
Website:
Address:
128 Sidney Street
Cambridge, MA 02139
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.